3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
27
Breast Neoplasms
23
Neoplasm Metastasis
14
Glioma
14
Carcinoma, Non-Small-Cell Lung
14
Lymphoma
12
Lung Neoplasms
11
Glioblastoma
11
Neuroblastoma
10
Lymphoma, Non-Hodgkin
9
Carcinoma, Renal Cell
9
Brain Neoplasms
9
Medulloblastoma
8
Ovarian Neoplasms
7
Neoplasms
7
Multiple Myeloma
7
Ependymoma
7
Carcinoma, Hepatocellular
7
Wilms Tumor
6
Thyroid Neoplasms
6
Sarcoma
6
Rectal Neoplasms
6
Pancreatic Neoplasms
6
Osteosarcoma
6
Melanoma
6
Fallopian Tube Neoplasms
6
Central Nervous System Neoplasms
6
Uterine Cervical Neoplasms
5
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
Magnetic Resonance Spectroscopy
×
Clear all
No trials found.